Genetic Basis of Rosacea

NCT02787616 | Completed

• 1 other identifier: R15006
• Study Type: observational
• Target: 306
• Locations: 1 country
• Sites: 1

Brief Summary

Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to develop gene expression profiles of papulopustular rosacea compared to those of normal skin. The investigators hope to better understand the abnormal gene functions that might contribute to this condition. This understanding may lead to the development of additional and better treatments for rosacea.

Conditions

Rosacea

Outcome Measures

Primary Outcomes (1)

• Targeted interrogation of alleles and assessment of rosacea co-morbidities.

  Up to 2 years

Study Arms (2)

Rosacea Group

Genetic: buccal swab

Non-Rosacea Group

Genetic: buccal swab

Interventions

buccal swab GENETIC

cheek swab for DNA sampling

Non-Rosacea Group; Rosacea Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

300 individuals will be enrolled, 150 with dermatologist verified rosacea and 150 without rosacea.

You may qualify if:

• Clinical signs and symptoms of rosacea (papulopustular or erythrotelangiectatic subtypes) present at enrollment as determined by the investigator
• All four grandparents of European descent
• Fitzpatrick skin type I or II
• Age 18 years or older

You may not qualify if:

• Unable or unwilling to provide written informed consent
• Concomitant facial or medical condition that obscures diagnosis of rosacea (such as malar erythema from lupus erythematosus)
• Acne vulgaris
• Unable or unwilling to provide peripheral blood sample (a few teaspoons)
• Inability for investigator to verify rosacea diagnosis on clinical examination due to rosacea treatment(s) leading to complete lack of signs and symptoms (such prior laser treatments, systemic tetracycline usage, etc.)
• Use of topical prescription medications or procedures to the face within one month of enrollment
• Women who are pregnant or lactating
• Eligibility Criteria for Non-Rosacea Group:
• No history of rosacea
• No clinical signs or symptoms of rosacea
• No family history of rosacea
• All four grandparents of European descent
• Fitzpatrick skin type I or II
• Age 18 years or older
• Unable or unwilling to provide written informed consent

Sponsors & Collaborators

• Stanford University: lead

Study Sites (1)

Stanford Dermatology

Redwood City, California, 94603, United States

Location

MeSH Terms

Conditions

Rosacea

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Dermatology

Study Record Dates

• First Submitted: April 18, 2016
• First Posted: June 1, 2016
• Study Start: April 13, 2012
• Primary Completion: November 16, 2018
• Study Completion: November 16, 2018
• Last Updated: September 26, 2019

Record last verified: 2019-09

Locations

US (1)